{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T03:43:25Z","timestamp":1789875805920,"version":"4.0.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,8,7]],"date-time":"2014-08-07T00:00:00Z","timestamp":1407369600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AIDS Behav"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1007\/s10461-014-0859-z","type":"journal-article","created":{"date-parts":[[2014,8,6]],"date-time":"2014-08-06T07:56:52Z","timestamp":1407311812000},"page":"743-751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials"],"prefix":"10.1007","volume":"19","author":[{"given":"Kawango","family":"Agot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy L.","family":"Corneli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ambia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela D. M.","family":"Kashuba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caleb","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ansley","family":"Lemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mookho","family":"Malahleha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lombaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lut","family":"Van Damme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,7]]},"reference":[{"issue":"5","key":"859_CR1","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1371\/journal.pctr.0020027","volume":"2","author":"L Peterson","year":"2007","unstructured":"Peterson L, Taylor D, Roddy R, et al. Tenofovir disoproxil fumarate for prevention of HIV infection in women: a phase 2, double-blind, randomized, placebo-controlled trial. PLOS Clin Trial. 2007;2(5):e27.","journal-title":"PLOS Clin Trial"},{"issue":"27","key":"859_CR2","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1056\/NEJMoa1011205","volume":"363","author":"RM Grant","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587\u201399.","journal-title":"N Engl J Med"},{"issue":"5","key":"859_CR3","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1202614","volume":"367","author":"L Damme Van","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367(5):411\u201322.","journal-title":"N Engl J Med"},{"issue":"5","key":"859_CR4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJMoa1108524","volume":"367","author":"JM Baeten","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399\u2013410.","journal-title":"N Engl J Med"},{"issue":"5","key":"859_CR5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1056\/NEJMoa1110711","volume":"367","author":"MC Thigpen","year":"2012","unstructured":"Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423\u201334.","journal-title":"N Engl J Med"},{"key":"859_CR6","unstructured":"Marrazzo J, Ramjee G, Nair G, et al. Pre-exposure prophylaxis for HIV in women: daily oral tenofovir, oral tenofovir\/emtricitabine, or vaginal tenofovir gel in the VOICE Study (MTN 003). Atlanta; 2013 [paper number 26LB]."},{"issue":"9883","key":"859_CR7","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/S0140-6736(13)61127-7","volume":"381","author":"K Choopanya","year":"2013","unstructured":"Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083\u201390.","journal-title":"Lancet"},{"issue":"9","key":"859_CR8","doi-asserted-by":"crossref","first-page":"e1001511","DOI":"10.1371\/journal.pmed.1001511","volume":"10","author":"JE Haberer","year":"2013","unstructured":"Haberer JE, Baeten JM, Campbell J, et al. Adherence to antiretroviral prophylaxis for HIV prevention: a substudy cohort within a clinical trial of serodiscordant couples in East Africa. PLoS Med. 2013;10(9):e1001511.","journal-title":"PLoS Med"},{"issue":"1","key":"859_CR9","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s10461-012-0172-7","volume":"17","author":"A Williams","year":"2013","unstructured":"Williams A, Amico KR, Bova C, Womack J. A proposal for quality standards for measuring medication adherence in research. AIDS Behav. 2013;17(1):284\u201397.","journal-title":"AIDS Behav"},{"issue":"6","key":"859_CR10","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1007\/s10461-013-0429-9","volume":"17","author":"KR Amico","year":"2013","unstructured":"Amico KR, Mansoor L, Corneli A, Torjesen K, Straten A. Adherence support approaches in biomedical HIV prevention trials: experiences, insights and future directions from four multisite prevention trials. AIDS Behav. 2013;17(6):2143\u201355.","journal-title":"AIDS Behav"},{"key":"859_CR11","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/QAI.0b013e3182794723","volume":"62","author":"J Adams","year":"2013","unstructured":"Adams J, Sykes C, Menezes P, et al. Tenofovir diphosphate and emtricitabine triphosphate concentrations in blood cells compared with isolated peripheral blood mononuclear cells: a new measure of antiretroviral adherence? J Acquir Immune Defic Syndr. 2013;62:260\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"859_CR12","unstructured":"TRUVADA\u00ae (emtricitabine\/tenofovir disoproxil fumarate) tablets, for oral use [prescribing information]. Foster City, CA: Gilead Sciences Inc; 2013."},{"key":"859_CR13","volume-title":"Applied thematic analysis","author":"G Guest","year":"2011","unstructured":"Guest G, MacQueen KM, Namey EE. Applied thematic analysis. Thousand Oaks: Sage; 2011."},{"key":"859_CR14","unstructured":"NVivo Qualitative Data Analysis Software. QSR International Pty Ltd; Version 9.2, 2010."},{"key":"859_CR15","unstructured":"Taylor D, Nanda K, Agot K, et al. The contraceptive use requirement and related study findings in the FEM-PrEP trial: Were existing contraceptive users more adherent to protocol? Microbicide 2012. Sydney, 2012."},{"key":"859_CR16","volume-title":"Handbook of interview research: context and method","author":"J Johnson","year":"2002","unstructured":"Johnson J. In-depth interviewing. In: Gubrium JF, Holstein JA, editors. Handbook of interview research: context and method. Thousand Oaks: Sage; 2002."},{"key":"859_CR17","volume-title":"Conducting in-depth interviews: a guide for designing and conducting in-depth interviews for evaluation input","author":"C Boyce","year":"2006","unstructured":"Boyce C, Neale P. Conducting in-depth interviews: a guide for designing and conducting in-depth interviews for evaluation input. Massachusetts: Pathfinder International; 2006."},{"key":"859_CR18","unstructured":"Wong C, Parker C, Ahmed K, et al. Participant motivation for enrolling and continuing in the FEM-PrEP HIV prevention clinical trial. 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur; 2013 [paper number WEAC0104]."},{"issue":"9654","key":"859_CR19","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1016\/S0140-6736(08)61842-5","volume":"372","author":"S Skoler-Karpoff","year":"2008","unstructured":"Skoler-Karpoff S, Ramjee G, Ahmed K, et al. Efficacy of Carraguard for prevention of HIV infection in women in South Africa: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372(9654):1977\u201387.","journal-title":"Lancet"},{"issue":"6","key":"859_CR20","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.cct.2009.07.002","volume":"30","author":"D Watson-Jones","year":"2009","unstructured":"Watson-Jones D, Baisley K, Rusizoka M, et al. Measurement and predictors of adherence in a trial of HSV suppressive therapy in Tanzania. Contemp Clin Trials. 2009;30(6):504\u201312.","journal-title":"Contemp Clin Trials"},{"key":"859_CR21","unstructured":"Amico KR, McMahan V, Anderson PL, et al. Adherence indicators and PrEP drug levels in the iPrEx study. 18th Conference on Retroviruses and Opportunistic Infections. Boston; 2011 [abstract 95LB]."}],"container-title":["AIDS and Behavior"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-014-0859-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10461-014-0859-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10461-014-0859-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T22:52:45Z","timestamp":1553640765000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10461-014-0859-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,7]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["859"],"URL":"https:\/\/doi.org\/10.1007\/s10461-014-0859-z","relation":{},"ISSN":["1090-7165","1573-3254"],"issn-type":[{"value":"1090-7165","type":"print"},{"value":"1573-3254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,7]]}}}